Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration
Silvio Danese, Federica Furfaro, Stefania Vetrano
Journal of Crohn s and Colitis (2017) Vol. 12, Iss. suppl_2, pp. S678-S686
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Novel and Emerging Therapies for Inflammatory Bowel Disease
Badr Al‐Bawardy, Raina Shivashankar, Deborah D. Proctor
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 132
Harnessing polymer-derived drug delivery systems for combating inflammatory bowel disease
Yuji Pu, Fan Xi, Zhuangzhuang Zhang, et al.
Journal of Controlled Release (2022) Vol. 354, pp. 1-18
Closed Access | Times Cited: 75
Faecal metabolome and its determinants in inflammatory bowel disease
Arnau Vich Vila, Shixian Hu, Sergio Andreu‐Sánchez, et al.
Gut (2023) Vol. 72, Iss. 8, pp. 1472-1485
Open Access | Times Cited: 73
Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD
Irma Tindemans, Maria E. Joosse, Janneke N. Samsom
Cells (2020) Vol. 9, Iss. 1, pp. 110-110
Open Access | Times Cited: 120
Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target
Olga Sukocheva, Hideki Furuya, Mah Lee Ng, et al.
Pharmacology & Therapeutics (2019) Vol. 207, pp. 107464-107464
Closed Access | Times Cited: 113
Roles of Ceramides and Other Sphingolipids in Immune Cell Function and Inflammation
Sabrin Albeituni, Johnny Stiban
Advances in experimental medicine and biology (2019), pp. 169-191
Closed Access | Times Cited: 91
Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease
Linshan Duan, Shu-Yu Cheng, Long Li, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 89
Review article: emerging drug therapies in inflammatory bowel disease
Laurie B. Grossberg, Konstantinos Papamichael, Adam S. Cheifetz
Alimentary Pharmacology & Therapeutics (2022) Vol. 55, Iss. 7, pp. 789-804
Closed Access | Times Cited: 57
Integrative Analysis of the Inflammatory Bowel Disease Serum Metabolome Improves Our Understanding of Genetic Etiology and Points to Novel Putative Therapeutic Targets
Antonio Di Narzo, Sander M. Houten, Roman Kosoy, et al.
Gastroenterology (2021) Vol. 162, Iss. 3, pp. 828-843.e11
Open Access | Times Cited: 56
Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review
Yasmin Zurba, Beatriz Gros, Mohammad Shehab
Biomedicines (2023) Vol. 11, Iss. 3, pp. 747-747
Open Access | Times Cited: 39
Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy
Olga Maria Nardone, Irene Zammarchi, Giovanni Santacroce, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2389-2389
Open Access | Times Cited: 30
Clinician’s Guide to Using Ozanimod for the Treatment of Ulcerative Colitis
Bruce E. Sands, Stefan Schreiber, Irina Blumenstein, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 12, pp. 2012-2025
Open Access | Times Cited: 27
Efficacy and Safety of Advanced Oral Small Molecules for Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Virginia Solitano, Sudheer K. Vuyyuru, John K MacDonald, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 11, pp. 1800-1816
Closed Access | Times Cited: 24
Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
Nurulamin M Noor, Alice Bourke, Sreedhar Subramanian
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1244-1260
Open Access | Times Cited: 10
S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy
Narges Rostami, Afshin Nikkhoo, Amir Ajjoolabady, et al.
Molecular Diagnosis & Therapy (2019) Vol. 23, Iss. 4, pp. 467-487
Closed Access | Times Cited: 57
Small molecule oral targeted therapies in ulcerative colitis
Uday N. Shivaji, Olga Maria Nardone, Rosanna Cannatelli, et al.
˜The œLancet. Gastroenterology & hepatology (2020) Vol. 5, Iss. 9, pp. 850-861
Closed Access | Times Cited: 56
New targets in inflammatory bowel disease therapy: 2021
Nathaniel A. Cohen, David T. Rubin
Current Opinion in Gastroenterology (2021) Vol. 37, Iss. 4, pp. 357-363
Open Access | Times Cited: 53
Translating Treg Therapy for Inflammatory Bowel Disease in Humanized Mice
Sushmita Negi, Sheetal Saini, Nikunj Tandel, et al.
Cells (2021) Vol. 10, Iss. 8, pp. 1847-1847
Open Access | Times Cited: 43
S1PR2/RhoA/ROCK1 pathway promotes inflammatory bowel disease by inducing intestinal vascular endothelial barrier damage and M1 macrophage polarization
Xuewen Wang, Shuhua Chen, Hong Xiang, et al.
Biochemical Pharmacology (2022) Vol. 201, pp. 115077-115077
Closed Access | Times Cited: 33
Intestinal Inflammation and Regeneration–Interdigitating Processes Controlled by Dietary Lipids in Inflammatory Bowel Disease
Soon Jae Kwon, Muhammad Sohaib Khan, Sang Geon Kim
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1311-1311
Open Access | Times Cited: 7
Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment—insights from Phase II and III trials
Sara Massironi, Federica Furfaro, Sarah Bencardino, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 9, pp. 761-787
Open Access | Times Cited: 7
Sphingolipids as mediators of inflammation and novel therapeutic target in inflammatory bowel disease
Olga Sukocheva, Elena Lukina, Eileen McGowan, et al.
Advances in protein chemistry and structural biology (2020), pp. 123-158
Closed Access | Times Cited: 42
Mesalazine and inflammatory bowel disease – From well-established therapies to progress beyond the state of the art
Pedro M. Veloso, Raúl Machado, Clarisse Nobre
European Journal of Pharmaceutics and Biopharmaceutics (2021) Vol. 167, pp. 89-103
Closed Access | Times Cited: 32
Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis ‐ a unique therapeutic target in inflammatory bowel disease
Jie Wang, Idan Goren, Bo Yang, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 55, Iss. 3, pp. 277-291
Open Access | Times Cited: 29
Horizon scanning: new and future therapies in the management of inflammatory bowel disease
Aditi Kumar, Philip J Smith
eGastroenterology (2023) Vol. 1, Iss. 2, pp. e100012-e100012
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top